John Day

35.7k total citations · 4 hit papers
391 papers, 14.4k citations indexed

About

John Day is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Genetics. According to data from OpenAlex, John Day has authored 391 papers receiving a total of 14.4k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Molecular Biology, 115 papers in Cardiology and Cardiovascular Medicine and 89 papers in Genetics. Recurrent topics in John Day's work include Neurogenetic and Muscular Disorders Research (84 papers), Cardiac Arrhythmias and Treatments (65 papers) and Genetic Neurodegenerative Diseases (62 papers). John Day is often cited by papers focused on Neurogenetic and Muscular Disorders Research (84 papers), Cardiac Arrhythmias and Treatments (65 papers) and Genetic Neurodegenerative Diseases (62 papers). John Day collaborates with scholars based in United States, France and United Kingdom. John Day's co-authors include Laura P.W. Ranum, Melinda L. Moseley, T. Jared Bunch, Brian G. Crandall, J. Peter Weiss, Jeffrey S. Osborn, K. Ricker, Heidi T. May, Peter A. Alsberg and Tami L. Bair and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

John Day

368 papers receiving 14.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Myotonic Dystrophy Type 2 Caused by a CCTG Expansion in Intron 1 of ZNF9

2001 918 citations Christina L. Liquori, K. Ricker et al. Science profile →
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

2016 736 citations Richard S. Finkel, John Day et al. profile →
Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH)

2002 508 citations John Day et al. profile →
Risdiplam in Type 1 Spinal Muscular Atrophy

2021 260 citations Giovanni Baranello, Basil T. Darras et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Day United States	62	6.8k	4.4k	4.1k	2.3k	1.9k	391	14.4k
Enrico Bertini Italy	71	14.3k 2.1×	1.3k 0.3×	3.2k 0.8×	4.4k 1.9×	1.5k 0.8×	637	22.6k
James A. Koziol United States	62	2.5k 0.4×	1.0k 0.2×	328 0.1×	1.4k 0.6×	904 0.5×	270	14.0k
Miguel Martín Spain	68	3.8k 0.6×	631 0.1×	828 0.2×	1.3k 0.6×	92 0.0×	519	18.7k
Joseph M. Smith United States	46	5.7k 0.8×	3.0k 0.7×	269 0.1×	327 0.1×	134 0.1×	141	12.9k
Heidi L. Rehm United States	53	13.8k 2.0×	3.6k 0.8×	1.5k 0.4×	1.8k 0.8×	1.0k 0.5×	186	31.4k
Euan A. Ashley United States	65	4.1k 0.6×	7.3k 1.6×	956 0.2×	129 0.1×	132 0.1×	342	16.6k
Rebecca A. Betensky United States	67	3.7k 0.5×	411 0.1×	1.2k 0.3×	2.6k 1.1×	2.7k 1.4×	299	14.9k
Yazhuo Zhang China	33	3.3k 0.5×	314 0.1×	403 0.1×	660 0.3×	490 0.3×	341	8.1k
John Allen United Kingdom	60	2.8k 0.4×	4.4k 1.0×	339 0.1×	238 0.1×	220 0.1×	385	14.9k
Robert H. Anderson United Kingdom	84	6.4k 0.9×	18.1k 4.1×	582 0.1×	396 0.2×	196 0.1×	1.1k	31.1k

Countries citing papers authored by John Day

Since Specialization

Citations

This map shows the geographic impact of John Day's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Day with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Day more than expected).

Fields of papers citing papers by John Day

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Day. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Day. The network helps show where John Day may publish in the future.

Co-authorship network of co-authors of John Day

This figure shows the co-authorship network connecting the top 25 collaborators of John Day. A scholar is included among the top collaborators of John Day based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Day. John Day is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Day, John, et al.. (2025). Defect Imaging With Frequency Domain Least-Squares Reverse Time Migration Using Analytical Green’s Functions.

Servais, Laurent, John Day, Darryl C. De Vivo, et al.. (2024). Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry. Journal of Neuromuscular Diseases. 11(2). 425–442. 27 indexed citations

Darras, Basil T., Giovanni Baranello, Odile Boespflug‐Tanguy, et al.. (2023). FIREFISH Parts 1 and 2: 36-month safety and efficacy of risdiplam in Type 1 spinal muscular atrophy (SMA) (P7-9.009). Neurology. 100(17_supplement_2). 1 indexed citations

Finkel, Richard S., Basil T. Darras, Jerry R. Mendell, et al.. (2023). Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG). Journal of Neuromuscular Diseases. 10(3). 389–404. 30 indexed citations

Crawford, Thomas O., et al.. (2023). P224 Effect of apitegromab on motor function at 36 months in patients with nonambulatory spinal muscular atrophy aged 2-12 years old. Neuromuscular Disorders. 33. S91–S91. 1 indexed citations

Rennert, Robert C., Jeffrey A. Steinberg, Takanori Fukushima, et al.. (2022). Histology of the Porous Oculomotorius: Relevance to Anterior Skull Base Approaches. Journal of Neurological Surgery Part B Skull Base. 84(3). 210–216. 2 indexed citations

Morelli, Kathryn H., Wenhao Jin, Assael A. Madrigal, et al.. (2022). MECP2-related pathways are dysregulated in a cortical organoid model of myotonic dystrophy. Science Translational Medicine. 14(651). eabn2375–eabn2375. 15 indexed citations

Holmes, DaJuanicia N., Roland Matsouaka, Anne B. Curtis, et al.. (2021). Sex Differences in Ablation Strategy, Lesion Sets, and Complications of Catheter Ablation for Atrial Fibrillation: An Analysis From the GWTG-AFIB Registry. Circulation Arrhythmia and Electrophysiology. 14(11). e009790–e009790. 13 indexed citations

Finkel, Richard S., John Day, Darryl C. De Vivo, et al.. (2020). RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design. Journal of Neuromuscular Diseases. 7(2). 145–152. 26 indexed citations

10.

Sellier, Chantal, Estefanía Cerro-Herreros, Markus Blatter, et al.. (2018). rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences. Nature Communications. 9(1). 2009–2009. 57 indexed citations

11.

Grasa, Eduard, et al.. (2016). From protecting protocols to layers: Designing, implementing and experimenting with security policies in RINA. 1–7. 12 indexed citations

12.

Johnson, Andrew P., Matthew E. Hardee, John Day, et al.. (2015). A case of cutaneous Rosai-Dorfman disease (CRDD) with underlying calvarial involvement and absence of BRAFV600E mutation. JAAD Case Reports. 1(6). 408–411. 8 indexed citations

13.

Miller, John M., David E. Krummen, Paul Clopton, et al.. (2013). Abstract 16890: Ablation of Atrial Fibrillation Rotors and Focal Sources Improves Outcome Over Conventional Ablation Alone in Independent Laboratories: Multicenter Validation of Focal Impulse and Rotor Modulation (FIRM). Circulation. 128. 3 indexed citations

14.

May, Heidi T., Jeffrey L. Anderson, Joseph B Muhlestein, et al.. (2011). Abstract 14699: Vitamin D Excess Is Significantly Associated with Risk of Atrial Fibrillation. Circulation. 124. 4 indexed citations

15.

Christensen, Nedra, Shiquan Wang, John Day, et al.. (2010). Warfarin Knowledge in Patients with Atrial Fibrillation: Implications for Safety, Efficacy, and Education Strategies. Cardiology. 116(1). 61–69. 50 indexed citations

16.

Liquori, Christina L., K. Ricker, Melinda L. Moseley, et al.. (2001). Myotonic Dystrophy Type 2 Caused by a CCTG Expansion in Intron 1 of ZNF9. Science. 293(5531). 864–867. 918 indexed citations breakdown →

17.

Day, John, Joseph A. DiGiuseppe, Charles J. Yeo, et al.. (1996). Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Human Pathology. 27(2). 119–124. 150 indexed citations

18.

Day, John & Hubert Zimmermann. (1995). The OSI reference model. IEEE Computer Society Press eBooks. 38–44. 10 indexed citations

19.

Alsberg, Peter A. & John Day. (1976). A principle for resilient sharing of distributed resources. International Conference on Software Engineering. 562–570. 298 indexed citations

20.

Day, John & Rhoda F. Grell. (1966). Radiation-induced non-disjunction and loss of chromosomes in Drosophila melanogaster females. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 3(6). 503–509. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact